I'm more interested in them getting to the next dose of Lux. I really hope they are not slow walking Lux. The FDA meeting on TUS monotherapy is not critical at this moment since we are early in the Aptivate expansion trail. I'm fine if they get it done within the next few months.
Market Data 
Markets 
AI
